| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/14/1999 | US5952325 Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists |
| 09/14/1999 | US5952322 Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| 09/14/1999 | US5952305 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| 09/14/1999 | US5952294 Peptidyl prodrugs and methods of making and using the same |
| 09/14/1999 | US5952212 Anticarcinogenic agents and antidiabetic agents |
| 09/14/1999 | US5951976 Vaccinating a mammal by administering a composition comprising an opsonin-enhanced cell comprising said selected antigen with the provision the opsonin does not bind to a receptor for a fragment of c33 |
| 09/14/1999 | US5951975 Immunization with a foreign artificial target antigen to promote a cytotoxic t-lymphocyte response; loading cultured tumor cells with antigen; deactivating the cells; immunizing with the cell to get a response to unmodified tumor |
| 09/14/1999 | US5951974 At least about 15%, preferably about 30%, of the interferon conjugates have a nonantigenic alkylpolyether attached to a preferential histidine residue; high activity; reacting an n-oxycarbonyloxyimide at acidic ph |
| 09/14/1999 | CA2174598C Use of an inhibitor of an hmg-coenzyme-a reductase to prevent aging of the skin or to stimulate the process of epidermal renewal |
| 09/14/1999 | CA2159449C Oesteoblast growth stimulating composition containing pdgf and vitamin d |
| 09/14/1999 | CA2144125C Use of sulfonic acids as antiageing agents in a cosmetic or dermatologic composition |
| 09/14/1999 | CA2071446C Synthetic catalytic oligonucleotide structures |
| 09/14/1999 | CA2006356C Arylpiperazinylbutyl-dihydroindoles and related compounds |
| 09/14/1999 | CA1340743C Compositions for the treatment of ostoporosis in humans |
| 09/10/1999 | WO1999045127A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045126A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045110A1 V-like domain binding molecules |
| 09/10/1999 | WO1999045029A1 New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide |
| 09/10/1999 | WO1999045027A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 09/10/1999 | WO1999045016A2 Novel prodrugs for phosphorus-containing compounds |
| 09/10/1999 | WO1999045011A1 Glycine transport inhibitors |
| 09/10/1999 | WO1999045009A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 09/10/1999 | WO1999044998A1 Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists |
| 09/10/1999 | WO1999044994A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | WO1999044989A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | WO1999044988A2 Method for preparing sulfanyl-type endothelin receptor antagonists |
| 09/10/1999 | WO1999044987A1 NON-PEPTIDE GnRH AGENTS |
| 09/10/1999 | WO1999044986A1 Acylated aminoacids for increasing the uptake of selected substances by organisms |
| 09/10/1999 | WO1999044640A1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
| 09/10/1999 | WO1999044636A2 Il-12 enhancement of immune responses to t-independent antigens |
| 09/10/1999 | WO1999044629A2 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | WO1999044623A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | WO1999044620A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 09/10/1999 | WO1999044618A1 Chemical compounds and their use to elevate pyruvate dehydrogenase activity |
| 09/10/1999 | WO1999044613A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v1a and v2 receptors |
| 09/10/1999 | WO1999044610A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | WO1999044607A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/10/1999 | WO1999044606A1 Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/10/1999 | WO1999044602A1 Inflammatory cell inhibitors |
| 09/10/1999 | WO1999044601A1 Fluoxetine hydrochloride for decreasing hot flashes |
| 09/10/1999 | WO1999044600A1 Cancer management with tamoxifen and gammalinolenic acid |
| 09/10/1999 | WO1999044597A2 Use of macrolide compounds for the treatment of ards |
| 09/10/1999 | WO1999044596A2 Glycine transport inhibitors |
| 09/10/1999 | WO1999033967A3 Novel nucleic acid and polypeptide with homology to the tnf-receptors |
| 09/10/1999 | WO1999033850A8 NOVEL β-LACTAMASE AND DD-PEPTIDASE INHIBITORS |
| 09/10/1999 | WO1999033840A3 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha1-blocking action |
| 09/10/1999 | WO1999033793A3 Prodrugs of aspartyl protease inhibitors |
| 09/10/1999 | WO1999032514A3 Sag: sensitive to apoptosis gene |
| 09/10/1999 | WO1999032477B1 Ortho-anthranilamide derivatives as anti-coagulants |
| 09/10/1999 | WO1999032099A3 Use of fucane for regulating the reconstruction of connective tissues |
| 09/10/1999 | WO1999027949A9 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE |
| 09/10/1999 | WO1999023078A3 Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists |
| 09/10/1999 | CA2323176A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/10/1999 | CA2323173A1 Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/10/1999 | CA2322856A1 Cancer management with tamoxifen and gammalinolenic acid |
| 09/10/1999 | CA2322838A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 09/10/1999 | CA2322684A1 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | CA2322664A1 Enhanced prodrug activation |
| 09/10/1999 | CA2322621A1 V-like domain binding molecules |
| 09/10/1999 | CA2322541A1 Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists |
| 09/10/1999 | CA2322486A1 Inflammatory cell inhibitors |
| 09/10/1999 | CA2322444A1 Non-peptide gnrh agents |
| 09/10/1999 | CA2322294A1 Il-12 enhancement of immune responses to t-independent antigens |
| 09/10/1999 | CA2322226A1 Method for preparing sulfanyl-type endothelin receptor antagonists |
| 09/10/1999 | CA2322207A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | CA2322164A1 Glycine transport inhibitors |
| 09/10/1999 | CA2322136A1 Glycine transport inhibitors |
| 09/10/1999 | CA2322051A1 New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphthyl)ethyl)amide |
| 09/10/1999 | CA2321737A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | CA2321685A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | CA2321648A1 Fluoxetine hydrochloride for decreasing hot flashes |
| 09/10/1999 | CA2321620A1 Acylated aminoacids for increasing the uptake of selected substances by organisms |
| 09/10/1999 | CA2317502A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | CA2263392A1 Ipriflavone preparation process |
| 09/10/1999 | CA2249661A1 Novel compounds |
| 09/09/1999 | DE19809635A1 Verfahren zur Darstellung von Endothelinrezeptorantagonisten vom Sulfanyltyp A process for the preparation of endothelin receptor antagonists of Sulfanyltyp |
| 09/09/1999 | DE19809144A1 Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten New asymmetrically substituted carboxylic acid derivatives, their preparation and use as a mixed ET¶LAMBDA¶ / ET¶B¶ receptor antagonists |
| 09/09/1999 | DE19808192A1 Diisopropylfluorophosphatase sowie deren Verwendung und Herstellung Diisopropyl fluorophosphatase and their use and production |
| 09/08/1999 | EP0940391A2 Quinoline derivatives as tachykinin NK3 receptor antagonists |
| 09/08/1999 | EP0940386A1 Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them |
| 09/08/1999 | EP0940143A2 Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/08/1999 | EP0940142A2 Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/08/1999 | EP0939821A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 09/08/1999 | EP0939820A1 Nucleic acid sequences that encode a cell growth regulatory protein and uses thereof |
| 09/08/1999 | EP0939816A1 Circularly permuted erythropoietin receptor agonists |
| 09/08/1999 | EP0939807A2 Secreted proteins and polynucleotides encoding them |
| 09/08/1999 | EP0939806A1 Fanconi gene 1 |
| 09/08/1999 | EP0939767A1 Modified factor viii |
| 09/08/1999 | EP0939766A2 Synthesis of soluble beta-sheet forming peptides |
| 09/08/1999 | EP0939760A2 1-thiogalactose derivatives |
| 09/08/1999 | EP0939759A2 Saccharide derivatives |
| 09/08/1999 | EP0939758A1 HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS |
| 09/08/1999 | EP0939757A1 Novel integrin receptor antagonists |
| 09/08/1999 | EP0939656A1 Gene delivery and expression in areas inaccessible to direct protein delivery |
| 09/08/1999 | EP0939644A1 Enhanced stimulation of erythropoiesis |
| 09/08/1999 | EP0939639A1 Methods and compositions for reducing or eliminating post-surgical adhesion formation |
| 09/08/1999 | EP0939637A1 Method of treating sinusitis with uridine triphosphates and related compounds |
| 09/08/1999 | EP0939634A1 Il-8 receptor antagonists |
| 09/08/1999 | EP0939632A1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS |
| 09/08/1999 | EP0939628A1 Thiol sulfone metalloprotease inhibitors |